Quite a few Seattle biotechies are quietly gearing up for the always-important American Society of Clinical Oncology meeting from June 4 to 8 in Chicago.
One of the big national headlines this week came when Amgen
Sometimes a startup is born after a couple old friends bump into each other after years of going their separate ways. That’s how Seattle Sensor Systems got an infusion of new vision and enthusiasm early this year, when Dendreon veteran Carole Spangler re-connected with UW researcher Clem Furlong on a portable technology for spotting pathogens.
Genomics pioneer J. Craig Venter made international news a couple weeks ago when he engineered the first bacterial cell with an entirely synthetic genome. But he actually had a lot of help. One of the key players he relied on behind the scenes was a privately held company in Bothell, Wash., called Blue Heron Biotechnology.
- Illume's iZUP Mobile App Padlocks Cell Phones to Eliminate the Temptation to Talk or Text While Driving
- Glaxo Stops Study of Sirtris "Red Wine" Drug in Cancer Patients
- C-Crete Wins MIT $100K for Making Cleaner Concrete
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at firstname.lastname@example.org, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
More from The Motley Fool
Today's Workers Aren't Optimistic About Raises and Promotions, Data Shows
Surprisingly, a large number of workers across the globe think their chances of a pay or title boost are pretty low. Here's how to bust out of that cycle and propel your career forward.
Could These High-Flying Tech Stocks Start Paying a Dividend?
Alphabet, Facebook, and Adobe don't do it yet, but that could change sooner than you think.
Will Rising Rates Bail Out Social Security's Trust Fund?
Interest-rate increases could boost available funding -- but there's a catch.